Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancerNeil A. O’Brien, Dennis J. Slamon|Breast Cancer Research|2020Cited by 155